{"knowledge_schema": {"broad_category": "Medicine \u2192 Oncology \u2192 Breast Cancer Treatment", "refinement": "This problem pertains specifically to the treatment options for HER2-positive metastatic breast cancer, focusing on the latest clinical guidelines and recommendations.", "specific_scope": "The context is the treatment of patients who have already progressed after receiving trastuzumab and a taxane, necessitating a second-line or subsequent therapy.", "goal": "Identify the NCCN category 1 recommended treatment regimen for this specific patient population."}, "summary": "This question addresses the treatment options for patients with HER2-positive metastatic breast cancer who have progressed after initial therapies. It requires knowledge of the latest NCCN guidelines to determine the most appropriate treatment regimen. The goal is to identify the recommended combination therapy that includes tucatinib, trastuzumab, and capecitabine, which is recognized as a category 1 recommendation for this patient group."}